Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.56 |
| ▸ | F7 | P08709 | 4/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | F3 | P13726 | 4/20 | 0.56 |
| ▸ | PPARD | Q03181 | 4/20 | 0.56 |
| ▸ | PPARA | Q07869 | 4/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4755168 | 1.00 | ALDH1A1 (0.56) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL23648282 | 1.00 | ALDH1A1 (0.56) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL14612882 | 1.00 | ALDH1A1 (0.56) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL23648284 | 1.00 | ALDH1A1 (0.56) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL1325085 | 0.92 | TRPV1 (0.64) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL7845617 | 0.92 | TRPV1 (0.64) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL1325082 | 0.92 | TRPV1 (0.64) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL18489893 | 0.92 | TRPV1 (0.64) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL22539035 | 0.92 | TRPV1 (0.64) | ALDH1A1PPARGF7CYP19A1F3 | |
| SCHEMBL1325084 | 0.92 | TRPV1 (0.64) | ALDH1A1PPARGF7CYP19A1F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2010508261-A | — | — | 2010-03-18 | — | — | JP | claimed |
| EP-2129646-A2 | OMEGA-3 LIPID COMPOUNDS | Pronova Biopharma Norge AS (NO) | 2009-12-09 | — | — | EP | claimed |
| WO-2008132552-A2 | OMEGA-3 LIPID COMPOUNDS | PRONOVA BIOPHARMA NORGE AS (US) | 2008-11-06 | — | — | WO | claimed |
| US-12465580-B2 | Substituted fatty acids for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-11-11 | — | — | US | disclosed |
| US-20240156760-A1 | SUBSTITUTED FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| US-11911354-B2 | Substituted fatty acids for treating non-alcoholic steatohepatitis | BASF (NO) | 2024-02-27 | — | — | US | disclosed |
| US-20220280459-A1 | SUBSTITUTED FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2022-09-08 | — | — | US | disclosed |
| EP-3210972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017093732-A1 | LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE | BIOZEP AS (NO) | 2017-06-08 | — | — | WO | disclosed |
| EP-2580204-B1 | CYSTEAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NASH | KRISANI BIOSCIENCE (P) LTD (IN) | 2017-03-08 | — | — | EP | disclosed |
| WO-2009134147-A1 | LIPID COMPOSITIONS CONTAINING DERIVATIVES OF EPA AND DHA AN THEIR USE THEREOF | PRONOVA BIOPHARMA NORGE AS (NO) | 2009-11-05 | — | — | WO | disclosed |
| WO-2008139261-A2 | OMEGA-3 LIPID COMPOUND | PRONOVA BIOPHARMA NORGE AS (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465580-B2 | Substituted fatty acids for treating non-alcoholic steatohepatitis | SLC10A1, LIPC, FABP1 | ALDH1A1 443/4885PPARG 30/4885F7 1250/4885 |
| US-20240156760-A1 | SUBSTITUTED FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | SLC10A1, LIPC, FABP1 | ALDH1A1 443/4885PPARG 30/4885F7 1250/4885 |
| US-20220280459-A1 | SUBSTITUTED FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | SLC10A1, LIPC, FABP1 | ALDH1A1 443/4885PPARG 30/4885F7 1250/4885 |
| US-11911354-B2 | Substituted fatty acids for treating non-alcoholic steatohepatitis | SLC10A1, LIPC, FABP1 | ALDH1A1 443/4885PPARG 30/4885F7 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.